SCHEMBL3758562

SCHEMBL3758562

O=[N+]([O-])c1ccc2oc(C=S)nc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.56
NPC1 O15118 7/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
MAPT P10636 5/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
ALDH1A1 P00352 3/20 0.53
MCL1 Q07820 1/20 0.53
ATM Q13315 1/20 0.53
MMP2 P08253 2/20 0.47
MMP9 P14780 2/20 0.47
MMP8 P22894 2/20 0.47
MMP13 P45452 2/20 0.47
POLB P06746 1/20 0.45
PSMB8 P28062 1/20 0.43
DAGLA Q9Y4D2 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TXNRD1 Q16881 1/20 0.41
TXNRD3 Q86VQ6 1/20 0.41
TXNRD2 Q9NNW7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11443651 0.87 MEN1 (0.62) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL3856571 0.85 RAB9A (0.56) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL11489586 0.80 RAB9A (0.60) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL5799175 0.79 RAB9A (0.51) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL5799184 0.79 RAB9A (0.51) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL15172875 0.78 RAB9A (0.61) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL2420144 0.78 RAB9A (0.61) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL29362134 0.78 RAB9A (0.61) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL10173106 0.76 RAB9A (0.65) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL2060733 0.76 ALDH1A1 (0.61) RAB9ANPC1SMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838543-B2 Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles ELI LILLY AND COMPANY (US) 2010-11-23 US disclosed
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-07-02 US disclosed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 EP disclosed
EP-1828177-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2007-09-05 EP disclosed
WO-2006066173-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R RAB9A 1154/4885NPC1 689/4885SMN1; SMN2 2294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.